HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Screen & Chart at the same time

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Mineralys Therapeutics, Inc.

Contributing Author

Recent Articles by Mineralys Therapeutics, Inc.

May-06
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update MLYS GlobeNewswire
May-05
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) MLYS GlobeNewswire
May-05
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference MLYS GlobeNewswire
Apr-29
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026 MLYS GlobeNewswire
Mar-24
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer MLYS GlobeNewswire
Mar-16
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) MLYS GlobeNewswire
Mar-12
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update MLYS GlobeNewswire
Mar-09
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results MLYS GlobeNewswire
Mar-09
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 MLYS GlobeNewswire
Feb-26
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) MLYS GlobeNewswire
Feb-11
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) MLYS -6.45% GlobeNewswire
Jan-06
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 MLYS GlobeNewswire
Dec-12
Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup MLYS GlobeNewswire
Nov-26
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) MLYS GlobeNewswire
Nov-10
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update MLYS +17.04% MLYS +5.87% GlobeNewswire
Nov-07
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 MLYS GlobeNewswire
Nov-05
Mineralys Therapeutics to Participate in Upcoming Investor Conferences MLYS -6.66% MLYS GlobeNewswire
Nov-03
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025 MLYS GlobeNewswire
Oct-21
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 MLYS GlobeNewswire
Sep-30
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension MLYS GlobeNewswire
Sep-05
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need MLYS +5.07% GlobeNewswire
Sep-04
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares MLYS +13.23% GlobeNewswire
Sep-02
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock MLYS GlobeNewswire
Sep-02
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock MLYS +86.43% GlobeNewswire
Aug-12
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update MLYS GlobeNewswire
Aug-04
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 MLYS GlobeNewswire
Jun-30
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat MLYS GlobeNewswire
Jun-17
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria MLYS GlobeNewswire
May-24
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) MLYS GlobeNewswire
May-20
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection MLYS +5.09% GlobeNewswire
May-12
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update MLYS GlobeNewswire
May-07
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference MLYS GlobeNewswire
May-05
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 MLYS -7.49% MLYS GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)